Epidemiology (E3) consortium (N=70,723) were included. Each study provided non-refractive visual 156 impairment and blindness prevalence estimates stratified by age (10 years strata) and gender. refractive visual impairment and blindness were defined as best-corrected visual acuity (BCVA) worse 158 than 20/60 and 20/400 in the better eye, respectively. Using random effects meta-analysis, 159 prevalence rates were estimated according to age, gender, geographical area and time period (1991-160 2006; 2007-2012) . Since no data were available for Central and Eastern Europe, population 161 projections for numbers of affected people were estimated using Eurostat population estimates for 162
European high-income countries in 2000 and 2010. 163 Results: The age-standardized prevalence of non-refractive visual impairment in people aged 55 164 years or older decreased from 2.22% (95% confidence interval (CI): 1.34-3.10) in 1991 , to 0.83% 165 (95% CI: 0.38-1.28) in 2007 . It strongly increased with age in both time periods (up to 15.69 % 166 and 4.39% in subjects aged 85 or more in 1991-2006 and 2007-2012, respectively 
226

POPULATIONS AND METHODS
227
Studies and participants
228
To date, E 3 comprises data from 41 studies with a range of ophthalmic data on approximately 170,000
229 individuals from population-based and other studies (case-control, cases only, randomized trials).
27
230
The present study was based on the fourteen E 3 population-based studies that collected best-
231
corrected visual acuity (BCVA) data (n=70,723). Studies in the E 3 consortium were eligible for 232 inclusion in this analysis if they were population-based, and had available data on BCVA, together with 233 sex, age at measurement, and year of measurement.
234
As described in Table 1 , participants included in this meta-analysis were mainly of middle to late age.
235
Because only few studies included subjects younger than 55 years, we estimated prevalence of visual 236 impairment and blindness only in subjects above this age. Visual acuity measurements were 237 performed between 1991 and 2012. Designs and methods of included studies are described in
238
Supplementary Online material (available at aaojournal.org). All studies adhered to the tenets of the
239
Declaration of Helsinki, and relevant local ethical committee approvals with specific study consent
240
were obtained. 
253
Differences in visual impairment by age (in ten year age bands from 55-64 years to ≥85 years), sex,
254
time period (1991-2006 and 2007-2012 , using the median of study periods), and geographical
255
European region were examined. Countries were divided into three regions (Northern, Western, and 
290
RESULTS 291
Fourteen studies were included in the statistical analysis (Table 1) 
295
increasing prevalence with age was not so obvious in some studies, but this was mainly due to low 296 number of affected subjects, particularly in the older age groups. A significant inter-study variability in 297 age-specific prevalence estimates was observed, again especially in the older age groups.
298
In Table 2 , we estimated age-standardized prevalence rates of visual endpoints according to several 299 factors (sex, period of eye examination, and geographical area). Prevalence of all visual endpoints 300 tended to be somewhat higher in women, but the confidence intervals were largely overlapping with 301 those of men. Age-standardized prevalence rates of all visual endpoints were much lower in the most 
311
In Table 3 , we estimated the prevalence rates and their 95% confidence intervals, for each age-and In Table 4 , we estimated the total number of inhabitants of European high income countries, affected In a meta-analysis of population-based studies from high-income countries (including United States, 335 Australia, and Europe) performed in the 1990's, the prevalence rates for non-refractive visual 336 impairment according to US standards (BCVA<20/40) were very similar to our estimates, varying 337 from 0.56% in subjects aged 55 to 59 years to 23.73 % in subjects 80 years or older 16 (in comparison 338 with 0.72 % in subjects aged 55-64 years to 28.95% in those age 85 years or more for the 1991-2006 339 period in the present study). In the National Health and Nutrition Examination Study (NHANES), the 340 prevalence of non-refractive visual impairment (BCVA<20/40) in non-Hispanic whites aged 60 years 341 or more was 3.9% (95% CI: 3.3 %-4.6 %) in 1999-2002, increasing the GBD meta-analysis is also in favor of a decreasing prevalence of visual impairment in Northern 350 America (from 3.5% in 1990 to 2.5% in 2010 for presenting visual acuity (PVA)<20/60).
351
The results of the GBD meta-analysis are not directly comparable to the present study, since they 352 were based on presenting visual acuity (PVA), thus including visual impairment due to refractive 353 errors. However, the temporal trends were similar to our study. Indeed, in the GBD study, the 354 prevalence of visual impairment and blindness (PVA<20/60 and PVA<20/400, respectively) decreased 355 worldwide from 1990 to 2010. 25 This was in particular the case in European high-income countries, 356 with a prevalence of visual impairment in subjects aged 50 years or more estimated at 6.2% (95% 357 confidence interval (CI): 4.3%-9.5%) in 1990 and 3.9% (95% CI: 2.8%-6.6%) in 2010. 26 Since they 358 estimated that 47% of visual impairment was due to refractive errors at both time points, their 359 estimates appear somewhat higher than ours (2.22% and 0.83% for non-refractive visual impairment 360 and blindness, respectively). 361
In the present study, the prevalence of non-refractive visual impairment was also halved in the most 362 recent period (2.22% in 1991-2006 compared with 0.83% in 2007-2012) . This suggests that visual 363 impairment due to eye diseases has decreased with time. Unfortunately, causes of visual impairment 364 and blindness were available only in some of the included studies, mainly because of incomplete eye 365 examinations in many studies (in particular absence of assessment of lens opacities, impeding the 366 diagnosis of cataract, and absence of visual field testing, impeding the diagnosis of glaucoma, which 367 are leading causes of visual impairment). The decrease in non-refractive visual impairment is most 368 probably due to improvement in ophthalmological care over the last 20 years, with an easier access 369 to eye care professionals in most European countries and a better reimbursement of medical 370 expenses. In particular, surgical procedures for cataract surgery, and intraocular lenses, have 371 improved over the last 20 years, increasing its availability, safety, and results in terms of visual acuity. 372
Indeed, the proportion of visual impairment due to cataract has been reported to decrease in the last 373 20 years, worldwide, and in particular in industrialized countries.
14 Moreover, new ocular therapies 374 have been developed in this period, including intravitreal injections of anti-vascular endothelial 375 growth factor (VEGF) agents for exudative macular diseases (neovascular AMD, diabetic macular 376 edema, and macular edema due to retinal vein occlusion), which were introduced in 2006. [30] [31] [32] These 377 therapies have led to major improvements in the visual prognosis of these diseases, and most 378 probably contribute to a decrease in the overall prevalence of visual impairment. 34, 35 For instance, a 379 decrease of 50 % of the incidence of blindness due to AMD has been reported in Denmark, mainly 380 after the introduction of intravitreal therapies for AMD in 2006. 34 Two American studies, and a meta-analysis in Europe, 386 based on the E3 consortium, have also suggested that the prevalence of AMD may be lower in new 387 generations. [35] [36] [37] 388 Similar trends have been observed in the decrease of the prevalence of other age-related disorders, 389 in particular dementia. [38] [39] [40] This suggests that recent generations are aging differently, which is 390 probably due to multiple causes, such as changes in education, living conditions, lifestyle habits 391 (smoking, nutrition, physical activity), and medical care. In particular, generations born after World 392 War II, which are now entering old age, have experienced quite different living and nutritional 393 conditions than those born before, and may age differently. While it is usually projected that the 394 number of disabled older individuals will dramatically grow in future years because of the aging 395 population, these recent reports, including ours, suggest that these projections may be over-396 pessimistic. In this changing environment, epidemiological studies need to be repeated in order to 397 monitor the trends in the prevalence of age-related disorders and related disability. 398
Similarly to other reports, women tended to have higher age-standardized prevalence rates of visual 399 impairment and blindness, although this was mainly observed in the first time period (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) . In 400 the GBD meta-analysis, the prevalence of visual impairment was higher in women than in men in all 401 world regions. 25 In the NHANES study, women had higher prevalence rates of visual impairment, 402 both in 1999-2002 (1.5% versus 1.2% for males) and in 2006-2008 (1.9% versus 1.5%), but these 403 differences did not reach statistical significance after adjustment for age, ethnicity, poverty, 404 education, health insurance, and diabetes. Reasons for these potential differences in visual 405 impairment among men and women are unclear, and the differences appear to have decreased in 406 the more recent years in Europe. 407
The E3 consortium has provided a large data set to meta-analyze temporal trends for prevalence of 408 visual impairment across Europe. One of the strengths is that this meta-analysis was built not only on 409 published data, but also on unpublished data, which have not been included in previous estimates. 410
The size of the dataset is much larger than in previous meta-analyses of European subjects, in 411 particular for the most recent time period (2007) (2008) (2009) (2010) (2011) (2012) . For instance, the GBD meta-analysis included 412 only 2 European studies conducted in this time period, both performed in Spain and totaling 1600 413 participants, while for the same time period, the present-meta-analysis included 6 studies from 7 414
European countries, totaling more than 36,000 participants. The estimates were also derived from 415 raw data provided by each study following standardized procedures, in particular in the definition of 416 the different visual endpoints. 417
Limitations of this consortium meta-analysis include heterogeneity between studies. Contributing 418 studies inherently differed in study design and cohort sampling. To overcome this, we performed a 419 random-effect rather than a fixed-effect meta-analysis, assuming no different true effect between 420 studies. There are also differences between European countries in terms of urbanization, economy, 421 social class, education and lifestyle, which are known to influence eye diseases. Data on these 422 variables at an individual or study-specific level were not uniformly available, and therefore could not 423 be included in the present study. 424
Representativeness of the population samples is probably also heterogeneous among studies. In 425 order to assess whether the lower prevalence rates observed in the most recent studies might be 426 While the E3 consortium strives to include a maximum of European research groups involved in 432 ophthalmic epidemiology, participating studies were mostly from European high-income countries, 433 while no studies from Central and Eastern Europe could be included, except for a small sample from 434 Estonia. To our knowledge, only very few epidemiological studies including measurements of visual 435 acuity have been conducted in Central and Eastern Europe. For instance, only three such studies 436 were included in the GBD meta-analysis (including the sample from Estonia which is also included in 437 our meta-analysis).
26 However, the available data suggest that the prevalence of visual impairment 438 and blindness may be higher in Central and Eastern Europe than in European high-income 439 countries.
26 Thus, we decided not to extrapolate our findings to those areas of Europe. 440
Epidemiological studies conducted in these areas of Europe would be particularly informative. 441
In addition, as shown in Table 1 , the majority of participating studies collected data only in subjects 442 aged 55 years or more. We therefore could not estimate the prevalence of visual impairment below 443 this age. Finally, most participating studies included only measures of best-corrected visual acuity, 444 but not of presenting visual impairment, so it was only possible to estimate the prevalence of non-445 refractive visual impairment. The causes of visual impairment were also generally not available. 
